Related Experiment Video
Updated: Aug 14, 2026
09:01
Magnetic-, Acoustic-, and Optical-Triple-Responsive Microbubbles for Magnetic Hyperthermia and Pothotothermal Combination Cancer Therapy
Published on: May 22, 2020
Bleomycin Loaded Fe(III)-TA@HA Nanoplatform: Enabling Photoacoustic Imaging-Guided Intralymphatic Injection and
Xin Zhang1,2, Saisai Yue3, Peisen Zhang4
1Department of Nuclear Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Chaoyang District, Beijing100020, China.
ACS Applied Materials & Interfaces
|August 13, 2026
Summary
A new nanoplatform, Fe(III)-TA/BLM@HA, offers targeted photothermal-sclerosis therapy for lymphatic malformations (LMs). This approach shows enhanced efficacy and reduced treatment cycles compared to conventional bleomycin therapy.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Vascular Biology
Background:
- Lymphatic malformations (LMs) present significant treatment challenges due to incomplete resection and high recurrence rates.
- Conventional therapies like bleomycin (BLM) sclerotherapy have limitations, including adverse effects and variable efficacy.
- Intractable LMs require innovative therapeutic strategies for improved patient outcomes.
Purpose of the Study:
- To develop and evaluate a multifunctional nanoplatform for targeted therapy of lymphatic malformations.
- To integrate photoacoustic imaging guidance, targeted delivery, and synergistic photothermal-sclerosis therapy.
- To assess the efficacy and safety of the novel nanoassembly in preclinical LM models.
Main Methods:
- Fabrication of a metal-polyphenol nanoplatform (Fe(III)-TA/BLM@HA) using hyaluronic acid (HA) matrix-regulated biomineralization.
- Characterization of nanoassembly properties, including colloidal stability, photothermal conversion, and photoacoustic signal.
- In vitro assessment of targeting specificity to lymphatic endothelial cells (LECs) and synergistic cytotoxicity.
- In vivo evaluation in Balb/c mouse LM models using photoacoustic imaging for biodistribution and therapeutic efficacy assessment.
Main Results:
- The Fe(III)-TA/BLM@HA nanoassemblies demonstrated specific targeting of LECs via HA-LYVE-1 interaction.
- Nanoassemblies exhibited excellent stability, efficient photothermal conversion, and strong photoacoustic signals for guided injection.
- In vitro studies showed synergistic cytotoxicity superior to free BLM.
- In vivo studies confirmed precise delivery and effective LM resolution in 1-2 cycles with combined photothermal-sclerosis, compared to 3-4 cycles for free BLM.
Conclusions:
- Fe(III)-TA/BLM@HA represents a safe and effective therapeutic option for intractable lymphatic malformations.
- The multifunctional nanoplatform integrates advanced imaging and synergistic therapy for enhanced treatment outcomes.
- This approach holds significant translational potential for managing vascular anomalies.
